Older Non-Small Cell Lung Cancer Patients (/= 70 Years of Age) Treated with FirstLine MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
This trial studies the side effects of pembrolizumab with or without chemotherapy in treating patients with non-small cell lung cancer that has come back and has spread to other places in the body. Pembrolizumab is an immunotherapy that may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy works in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the tumor in older patients with non-small cell lung cancer.
This study is closed
Catherine Shu, MD
|Are you 70 years of age or older?
|Have you been diagnosed with non-small cell lung cancer that has spread to other parts of your body?
|Are you able to make regularly scheduled visits to the clinic for treatment and examinations?